Shattuck Labs Amends 8-K Regarding Director Departure

TL;DR

Shattuck Labs clarifies director Yauch's exit wasn't due to any company disagreements.

AI Summary

Shattuck Labs, Inc. filed an 8-K/A on June 11, 2024, to amend its previous filing regarding the departure of Director Dr. Michael J. Yauch, effective March 1, 2024. The amendment clarifies that Dr. Yauch's departure was not due to any disagreements with the company's management or its accounting practices or financial statements.

Why It Matters

This amendment provides clarity on a director's departure, assuring investors that it was not related to any internal disputes or financial irregularities.

Risk Assessment

Risk Level: low — The filing is an amendment to clarify a previous report and does not introduce new material risks.

Key Players & Entities

• Shattuck Labs, Inc. (company) — Registrant
• Dr. Michael J. Yauch (person) — Departing Director
• March 1, 2024 (date) — Effective date of departure
• June 11, 2024 (date) — Filing date of amendment

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share STTK The Nasdaq Global Se

Filing Documents

• d123131d8ka.htm (8-K/A) — 22KB
• 0001193125-24-159174.txt ( ) — 150KB
• sttk-20240301.xsd (EX-101.SCH) — 3KB
• sttk-20240301_lab.xml (EX-101.LAB) — 19KB
• sttk-20240301_pre.xml (EX-101.PRE) — 12KB
• d123131d8ka_htm.xml (XML) — 4KB

From the Filing

8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39593 81-2575858 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) 500 W. 5th Street , Suite 1200 Austin , TX 78701 (Address of principal executive offices including zip code) (512) 900-4690 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuance to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share STTK The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2024, Shattuck Labs, Inc. (the "Company") filed a Current Report on Form 8-K under Item 5.02 pursuant to which the Company announced that its Board of Directors (the "Board") had appointed Drs. Kate Sasser and Clay Siegall to the Board (the "Original Form 8-K"). At that time, the Board had not yet appointed Drs. Sasser and Siegall to any Board committees. In accordance with Securities and Exchange Commission rules, this amendment to the Original Form 8-K is being filed to report that effective June 11, 2024, the Board appointed Dr. Sasser to the Nominating and Corporate Governance Committee and Dr. Siegall to the Compensation Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Shattuck Labs, Inc. Date: June 11, 2024 By: /s/ Dr. Taylor Schreiber Dr. Taylor Schreiber Chief Executive Officer (principal executive officer)

View Full Filing

View this 8-K/A filing on SEC EDGAR